5s casino

As part of efforts to bring product development now manufactured in China closer to the U.S., Carl Bentzel prefers the island over México November 27, 2024 - 3:35 PM Washington D.C. - Carl Bentzel , a member of the Federal Maritime Commission , recommended that U.S. President-elect Donald Trump encourage manufacturing companies to relocate to Puerto Rico because of its territorial status, proximity, labor force, infrastructure and “a more stable political environment” than other countries, such as México. Financial Oversight and Management Board proposes financial settlement in landmark Special Education case For sale or rent dozens of properties belonging to Puerto Rico Public Buildings Authority 11 projects would be dealt with in the extraordinary sessionMcMahon’s misconduct allegations concern advocates for student safetyZETA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zeta Global Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

VirnetX To Webcast Company Update With CEO Kendall Larsen

To play Maria Callas, Angelina Jolie had to learn how to breathe againA DUP minister rebuffed a suggestion that there could be an extension of pub opening hours in Northern Ireland to celebrate the golden jubilee of the late Queen Elizabeth II in 2002, declassified files show. Stormont minister Maurice Morrow told an official he would not raise the issue with the Northern Ireland Executive , despite similar measures being considered in England and Wales. A file on planning arrangements for the jubilee celebrations reveals a series of civil service correspondences on how Northern Ireland would mark the occasion. It includes a letter sent on January 11 2001 from an official in the Office of the First Minister/Deputy First Minister (OFMDFM) to the Department of Social Development, advising that a committee had been set up in London to consider a programme of celebrations. The correspondence says: “One of the issues the committee is currently considering is the possibility of deregulating liquor licensing laws during the golden jubilee celebrations on the same lines as the arrangements made for the millennium. “It is felt that the golden jubilee bank holiday on Monday 3 June 2002 is likely to be an occasion on which many public houses and similar licensed premises would wish to stay open beyond normal closing time.” The letter said a paper had been prepared on the issue of extending opening hours. It adds: “You will note that paragraph seven of the paper indicates that the devolved administrations ‘would need to consider deregulation separately within their own jurisdictions’. “I thought that you would wish to be aware that this issue is receiving active consideration for England and Wales and to consider whether anything needs to be done for Northern Ireland.” Some months later a “progress report” was sent between officials in OFMDFM, which again raised the issue of licensing laws. It says: “I spoke to Gordon Gibson, DSD, about Terry Smith’s letter of 12 January 2001 about licensing laws: the matter was put to their minister Maurice Morrow (DUP) who indicated that he would not be asking the NIE (Northern Ireland Executive) to approve any change to current licensing laws in NI to allow for either 24 hour opening (as at the millennium) nor a blanket approval for extended opening hours as is being considered in GB. “In both cases, primary legislation would be required here and would necessitate consultation and the minister has ruled out any consultation process.” The correspondence says individual licensees could still apply for an extension to opening hours on an ad hoc basis, adding “there the matter rests”. It goes on: “DSD await further pronouncements from the Home Office and Gibson and I have agreed to notify each other of any developments we become aware of and he will copy me to any (existing) relevant papers. “Ministers may well come under pressure in due course for a relaxation and/or parity with GB.” The document concludes “That’s it so far...making haste slowly?” Emails sent between officials in the department the same month said that lord lieutenants in Northern Ireland had been approached about local events to mark the jubilee. One message says: “Lord lieutenants have not shown any enthusiasm for encouraging GJ celebrations at a local level. “Lady Carswell in particular believes that it would be difficult for LLs to encourage such activities without appearing political.”

T-cell malignancies account for about 10-15% of all lymphoid malignancies, and their treatment often involves chemotherapy, immunotherapy, or stem cell transplantation. These cancers can be particularly challenging due to their heterogeneity and resistance to traditional treatments. LAS VEGAS , Dec. 11, 2024 /PRNewswire/ -- T-cell malignancies are a group of cancers originating from the T-cells, a vital part of the immune system responsible for recognizing and combating foreign invaders. These cancers can develop when T-cells undergo genetic mutations, leading to uncontrolled growth and division. T-cell malignancies are generally categorized into two broad types: T-cell lymphomas and T-cell leukemias. T-cell lymphomas primarily affect the lymphatic system, involving lymph nodes and other lymphoid tissues, while T-cell leukemias impact the blood and bone marrow. These malignancies are often more aggressive and harder to treat than B-cell cancers due to their complex biology and resistance to conventional therapies. Symptoms can vary but typically include enlarged lymph nodes, fever, night sweats, and weight loss. Treatment options include chemotherapy, radiation therapy, and novel therapies like CAR T-cell therapy and targeted therapies, which are advancing the understanding and management of these challenging cancers. DelveInsight has recently released a series of epidemiology-based market reports focusing on T-cell malignancies including Acute Lymphoblastic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma . These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2020 to 2034 segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these T-cell malignancies markets individually. Acute Lymphocytic Leukemia Market Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a cancer that develops in the blood and bone marrow. It originates from immature white blood cells known as lymphocytes in the bone marrow and is marked by the excessive production of immature cells, referred to as lymphoblasts or leukemic blasts. As the bone marrow fails to produce sufficient red blood cells, healthy white blood cells, and platelets, individuals with ALL are more prone to anemia, frequent infections, and easy bruising or bleeding. Among the 7MM, the US accounted for the highest number of incident cases of acute lymphocytic leukemia. The total incident cases of acute lymphocytic leukemia in the US comprised approximately 6,800 cases in 2023 and are projected to increase during the forecast period. Among the type-specific cases of acute lymphocytic leukemia, B-acute lymphocytic leukemia accounted for nearly 85% of the cases, while T-acute lymphocytic leukemia accounted for nearly 15% in the US. The treatment paradigms of acute lymphocytic leukemia have been revolutionized with the advent of tyrosine kinase inhibitors targeting BCR-ABL1 (GLEEVEC [imatinib mesylate], SPRYCEL [dasatinib], and ICLUSIG [ponatinib]), monoclonal antibodies targeting CD20 (RITUXAN), antibody-drug conjugates targeting CD22 (BESPONSA), bispecific antibodies (BLINCYTO), CD19 chimeric antigen receptor T cell therapy (KYMRIAH and TECARTUS) , and others. As per DelveInsight analysis, in 2023, the market size for acute lymphocytic leukemia across the 7MM was around USD 1.6 billion , with projections indicating further growth by 2034. The United States dominated the market in 2023, contributing approximately USD 1.2 billion . ALL presents a significant market opportunity, with BLINCYTO currently leading the segment. Amgen continues to drive innovation in ALL through its BiTE Technology, receiving FDA approval in June 2024 . Additionally, Amgen is advancing a registration-enabling study to develop a subcutaneous injection formulation of blinatumomab. Acute Lymphocytic Leukemia Pipeline Therapies and Companies Orca-T: Orca Biosystems AUTO1/22: Autolus Therapeutics VENCLEXTA/VENCLYXTO (venetoclax): AbbVie and Roche (Genentech) Daratumumab: J&J Innovative Medicine IMBRUVICA (ibrutinib): Pharmacyclics (an AbbVie Company) JAKAFI (ruxolitinib): Incyte Corporation/Novartis VYXEOS (CPX-351): Jazz Pharmaceuticals Obecabtagene autoleucel (obe-cel): Autolus Therapeutics SNDX-5613 (revumenib): Syndax Pharmaceuticals UCART22: Cellectis ADCT-602: ADC Therapeutics WU-CART-007: Wugen For a comprehensive view of the acute lymphocytic leukemia market, check out the Acute Lymphocytic Leukemia Market Assessment Peripheral T-cell Lymphoma Market Peripheral T-cell lymphoma represents a heterogeneous collection of aggressive lymphomas arising from mature T-cells and natural killer cells, comprising approximately 10–15% of all non-Hodgkin lymphomas globally. PTCL is more prevalent in Asia compared to North America and Europe . PTCL has been reported to account for 25% of all NHL cases in Japan . The increased rate of T-cell lymphomas in Asia is attributed to the low incidence of follicular lymphomas. The total incident cases of PTCL in the 7MM were 26,000 cases in 2023; these cases are estimated to increase by 2034. As more targetable mutations are identified and new targeted therapies are developed, the range of treatment options for patients and oncologists continues to expand. However, with the rapid pace of drug approvals, it is crucial to ensure that adequate supporting data justifies the use of specific therapies in the appropriate treatment settings, whether as adjuvant, consolidation, first-line, or subsequent treatments. Peripheral T-cell lymphoma remains a significant therapeutic challenge due to its aggressive nature, rarity, and high heterogeneity. Conventional chemotherapy for PTCL typically involves anthracycline-based regimens (such as CHOP and EPOCH) or non-anthracycline alternatives (including platinum, etoposide, gemcitabine, and methylprednisolone). While the majority of patients initially undergo chemotherapy, nearly a quarter develop primary refractory disease. Many others relapse even after responding to induction chemotherapy, with a median overall survival of just six months. According to NCCN guidelines, specific PTCL subtypes are also treated with six cycles of CHOP-21 or CHOEP, often combined with involved-site radiation therapy. The FDA has approved several drugs for PTCL treatment, including BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), XALKORI (Crizotinib, Pfizer), and ADCETRIS (Brentuximab Vedotin, Seattle Genetics). Until recently, there was no established standard of care for first-line treatment in PTCL, leaving a significant gap in approved therapies. The approval of ADCETRIS in November 2018 by the US FDA has transformed the treatment landscape. ADCETRIS, in combination with chemotherapy, is now the first and only FDA-approved regimen for first-line treatment of adults with previously untreated systemic ALCL or other CD30-expressing PTCL. Notably, its approval came less than two weeks after submission under the FDA's real-time oncology review pilot program. Key players, such as Secura Bio, HUYA Bioscience International, Verastem, Solasia Pharma, Seagen, Dizal Pharmaceutical , and others, are evaluating their lead candidates in different stages of clinical development, respectively. As per the DelveInsight assessment, the total market size in the 7MM for PTCL was estimated to be ~USD 680 million in 2020, which is projected to show positive growth by 2034. This growth of the PTCL market is expected to be mainly driven by increased diagnosed incidence, patient awareness, and a robust clinical pipeline during the forecast period (2024–2034). PTCL Pipeline Therapies and Companies COPIKTRA (duvelisib): Secura Bio Linperlisib (YY-20394): Shanghai YingLi Pharmaceutical Golidocitinib (DZD4205) : Dizal Pharmaceuticals Nanatinostat + Valganciclovir: Viracta Therapeutics Lacutamab/IPH4102: Innate Pharma Sugemalimab (CS1001): CStone Pharmaceuticals AFM13: Affimed Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals AUTO4: Autolus MT-101: Myeloid Therapeutics KEYTRUDA (pembrolizumab): Merck Sharp & Dohme OPDIVO (nivolumab): Bristol Myers Squibb To gain a deeper understanding of the PTCL market, be sure to explore the Peripheral T-cell Lymphoma Market Outlook Cutaneous T-cell Lymphoma Market Cutaneous T-cell lymphomas are rare cancers that predominantly involve the skin. Some types progress slowly within the skin, while others may spread to the blood or lymph nodes. The most prevalent form of CTCL is mycosis fungoides, along with its leukemic variant, Sézary syndrome. Another frequently encountered group includes CD30-positive lymphoproliferative disorders (CD30+ LPDs). In 7MM, the United States accounted for the highest number of incident cases of CTCL, which is 46% of the total incident population of CTCL in 7MM in 2023, as per DelveInsight. In the US, out of all stage-specific cases of CTCL, Stage-IA accounted for the highest number of cases, followed by Stage-IB and Stage-IIB cases in 2023. There is currently no approved first-line therapy for early-stage (I–IIA) cutaneous T-cell lymphoma, highlighting a significant unmet need in this patient population. Treatment decisions for patients with mycosis fungoides and Sézary syndrome, both types of CTCL, are influenced by factors such as the extent of skin involvement, the type of lesions, and whether metastasis is present. Therapies for mycosis fungoides focus on either localized skin treatment or systemic approaches, allowing many patients to achieve long-term remission and maintain normal lives. In contrast, Sézary syndrome, marked by systemic involvement, often requires systemic therapies, either alone or in combination, to improve long-term outcomes. TARGRETIN, ADCETRIS, POTELIGEO, ZOLINZA, and ISTODAX are approved by the US FDA for the treatment of Mycosis Fungoides and Sezary Syndrome. Other systemic therapies such as interferons (alfa and gamma), methotrexate, and other retinoids (acitretin and isotretinoin) also offer clinical benefits but have only been evaluated in small studies. As per DelveInsight analysis, the market size of CTCL in the 7MM is expected to cross USD 780 million by 2034. This growth is mainly driven by advancements in targeted therapies, rising awareness of rare cancers, and increasing research and development investments. The adoption of innovative treatments such as monoclonal antibodies and checkpoint inhibitors, coupled with improved diagnostic technologies, is anticipated to enhance market expansion. Additionally, a growing patient population and supportive regulatory policies will further bolster market growth. CTCL Pipeline Therapies and Companies HyBryte (SGX301): Soligenix KINSELBY (resminostat): 4SC AG Lacutamab: Innate Pharma Explore in-depth for a comprehensive understanding of the Cutaneous T-cell Lymphoma Clinical Trials Anaplastic Large Cell Lymphoma Market Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin lymphoma, characterized by large, irregular lymphoid cells that express the CD30 antigen. ALCL accounts for approximately 1% of all NHL cases and 16% of T-cell lymphomas. ALK-positive ALCL is associated with conditions such as HIV, mycosis fungoides, and pulmonary or inflammatory pseudotumors. In contrast, ALK-negative ALCL is more commonly observed in older individuals and is frequently linked to extranodal disease involvement. As per DelveInsight's analysis, ALCL has a slightly higher incidence in men compared to women. ALK-positive ALCL typically affects children and adolescents, with a median age of 30 years, while ALK-negative ALCL tends to affect older adults, with a median age of 54 years. ALK-positive ALCL carries a better prognosis, with 5-year survival rates of 70% to 90% , compared to 40% to 60% for ALK-negative ALCL. The treatment of ALCL varies based on its subtype and stage. Systemic ALCL is commonly addressed with chemotherapy regimens such as CHOP or CHOEP, showing improved outcomes in ALK-positive cases. The key drugs used for the treatment of anaplastic large cell lymphoma are – Pfizer's XALKORI and Takeda's ADCETRIS. For relapsed or refractory cases, brentuximab vedotin has proven effective. Primary cutaneous ALCL is typically managed through radiation, surgery, or chemotherapy and generally has a good prognosis. Breast implant-associated ALCL is treated by removing the implant, with radiation or chemotherapy added if the disease has spread. The ALCL market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness. Additionally, the ALCL market size is expected to increase due to an increasing diagnosed prevalent population, awareness about the subtype of ALCL (Breast implant-associated ALCL), and an increase in R&D activity, which would essentially boost the commercial success of emerging therapies. Anaplastic Large Cell Lymphoma Pipeline Therapies and Companies AUTO4: Autolus Therapeutics SGN-35T: Seagen To access a complete analysis of the anaplastic large cell lymphoma market, visit Anaplastic Large Cell Lymphoma Market Assessment Adult T-cell Leukemia/Lymphoma Market Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive malignancy of mature T lymphocytes caused by infection with the human T-cell lymphotropic virus type 1 (HTLV-1). ATLL is classified into four clinical subtypes: acute, lymphomatous, chronic, and smoldering, each with distinct prognoses. The acute and lymphomatous forms are the most aggressive, with a median survival of less than a year without treatment. ATLL commonly affects adults aged 40–60 years and is associated with immunosuppression, hypercalcemia, and frequent involvement of skin, lymph nodes, and bone marrow. The global prevalence varies, but it is estimated that about 5–10% of individuals infected with HTLV-1 develop ATLL after decades of latency. Treatment for ATLL is challenging, as the disease presents with a wide range of clinical manifestations, from chronic to acute forms. First-line therapy often involves combination chemotherapy regimens, such as the CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) regimen, which has shown effectiveness in treating the aggressive forms of ATLL. For more refractory or relapsed cases, a bone marrow transplant may be considered as a curative option. Additionally, the use of denileukin diftitox, a fusion protein targeting CD25, has been approved for relapsed or refractory ATLL. Newer therapies are exploring the use of targeted agents, including histone deacetylase inhibitors (e.g., romidepsin) and lenalidomide, a potent immune-modulatory drug, to improve outcomes in patients with advanced disease. However, despite these options, ATLL treatment remains an area in urgent need of innovation to improve survival rates and quality of life for patients. The Adult T-cell leukemia/lymphoma market is expected to witness significant growth in the coming years, driven by advancements in diagnostics, therapies, and an increased understanding of the disease. Additionally, innovations in immunotherapies, including monoclonal antibodies, CAR-T cell therapies, and combination regimens, are expected to revolutionize the treatment landscape, offering hope for improved survival rates. Moreover, ongoing research into biomarkers and precision medicine will likely lead to better patient stratification and more effective treatment plans. Overall, the ATLL market is poised for expansion, attracting investments in research and development, clinical trials, and regulatory approvals to meet the growing need for better, more accessible therapies. Adult T-cell Leukemia/Lymphoma Pipeline Therapies and Companies Valemetostat Tosylate: Daiichi Sankyo BEAM-201: Beam Therapeutics Inc. Tolinapant: Astex Pharmaceuticals To delve into the adult T-cell leukemia/lymphoma market landscape in more detail, access the Adult T-cell Leukemia/Lymphoma Market Report Trending Oncology Reports Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Man City crisis deepens with loss to Juventus in Champions League as Barcelona and Arsenal win Manchester City plunged deeper into trouble in the Champions League by losing 2-0 at Juventus in the latest setback in a scarcely believable run of poor results for the ailing English champions. City dropped to 22nd place in the 36-team standings and only the top 24 advances. Reaching the knockout stage looked a certainty before the season for a team that was European champion in 2022 and has won the last four Premier League titles. It's not anymore as City manager Pep Guardiola battles injuries and an apparent loss of belief among his players. Arsenal beat Monaco 3-0 and Barcelona won 3-2 at Borussia Dortmund. Rape allegation against Jay-Z won’t impact NFL's relationship with music mogul, Goodell says IRVING, Texas (AP) — NFL Commissioner Roger Goodell says a rape allegation against rapper Jay-Z won’t impact the NFL's relationship with the music mogul. Jay-Z's company Roc Nation has produced some of the NFL’s entertainment presentations including the Super Bowl halftime show. A woman who previously sued Sean “Diddy” Combs alleging she was raped at an awards show after-party in 2000 amended the lawsuit Sunday to include an allegation that Jay-Z was also at the party and participated in the sexual assault. Jay-Z says the rape allegation made against him is part of an extortion attempt. The NFL teamed up with Jay-Z’s Roc Nation in 2019 for events and social activism. The league and the entertainment company extended their partnership a few months ago. Juan Soto gets free luxury suite and up to 4 premium tickets for home games in $765M Mets deal DALLAS (AP) — Juan Soto gets free use of a luxury suite and up to four premium tickets behind home plate for regular-season and postseason New York Mets home games as part of his record $765 million, 15-year contract. The Mets agreed to provide personal team security for the All-Star outfielder and his family at the team’s expense for all spring training and regular-season home and road games, according to details of the agreement obtained by The Associated Press. New York agreed to assist Soto’s family for in-season travel arrangements, guaranteed he gets uniform No. 22 and included eight types of award bonuses. Ohio politician proposes make flag planting a felony after fight in Michigan rivalry game An Ohio politician has seen enough flag planting. Republican state Rep. Josh Williams said Wednesday on social media he's introducing a bill to make flag planting in sports a felony in the state. His proposal comes after the Nov. 30 fight at the Michigan-Ohio State rivalry football game when the Wolverines beat the Buckeyes 13-10 and then attempted to plant their flag at midfield. A fight ensued and police had to use pepper spray to disperse the players. Former Oklahoma quarterback Baker Mayfield famously planted a flag in the middle of the field at Ohio State after the Sooners beat the Buckeyes in 2017. FIFA confirms Saudi Arabia as 2034 World Cup host despite human rights concerns ZURICH (AP) — Saudi Arabia has been officially confirmed by FIFA as host of the 2034 World Cup in men’s soccer. The Saudi bid was the only candidate and was acclaimed by the applause of more than 200 FIFA member federations. They took part remotely in an online meeting hosted in Zurich on Wednesday by the soccer body’s president Gianni Infantino. The decision was combined with approving the only candidate to host the 2030 World Cup. Spain, Portugal and Morocco will co-host in a six-nation project, with Argentina, Paraguay and Uruguay each getting one of the 104 games. The South American connection will mark the centenary of Uruguay hosting the first World Cup in 1930. Jimmy Butler says he's not worrying about his future with Heat amid trade speculation Jimmy Butler knows there are tons of questions about his future with the Miami Heat. He might get traded, he might leave as a free agent next summer, he might exercise a $52.4 million option to return to the Heat or he might get a new contract. He isn't sure what will happen. The Heat forward spoke out about trade speculation Wednesday, telling reporters after practice that he doesn’t mind his name being in the rumor mill. US Biathlon officials ignored sexual harassment and abuse of female racers for decades, athletes say Sexual abuse and harassment by coaches and others who held positions of power over women on the U.S. Biathlon team were ignored or excused over decades by officials more concerned with winning medals than holding offenders accountable. That's according to Olympians and other biathletes interviewed by The Associated Press. While the men climbed the sport's ranks, these women say they were forced to end their careers early. The women and others describe a culture of misogyny and say they faced retaliation for speaking up. Three of the men denied allegations they were either part of the abuse or ignored allegations of abuse. A fourth did not respond to AP requests for comment. Tulane QB Mensah transfers to Duke; Mississippi State’s Van Buren, Cal’s Mendoza enter portal Former Tulane quarterback Darian Mensah has already found a new program in Duke, while Mississippi State’s Michael Van Buren Jr. and Cal’s Fernando Mendoza are exploring changes of their own in the transfer portal. Mensah is a redshirt freshman with three years of eligibility remaining. He told ESPN on Wednesday he has transferred to Duke. He attended the Blue Devils men’s basketball game against Incarnate Word on Tuesday night. The Blue Devils will face Mississippi in the Gator Bowl, but without 2024 starting quarterback Maalik Murphy and backup Grayson Loftis, who also entered the portal. All-Star left-hander Garrett Crochet acquired by Red Sox from White Sox for prospects DALLAS (AP) — All-Star left-hander Garrett Crochet has been acquired by the Boston Red Sox from the Chicago White Sox for four prospects. Catcher Kyle Teel, infielder Chase Meidroth, right-hander Wikelman Gonzalez and outfielder Braden Montgomery are headed to Chicago. The 25-year-old Crochet was 6-12 with a 3.58 ERA in 32 starts for a White Sox team that went 41-121. It's the most losses for any club since 1900. He was picked for the AL All-Star team in his first season as a starter. Selected 11th overall by Chicago in the 2020 amateur draft, Crochet made his big league debut that September. He had Tommy John surgery in April 2022. Lindsey Vonn savors chance to test out World Cup course as a forerunner in comeback bid at age 40 BEAVER CREEK, Colo. (AP) — Lindsey Vonn is trying to take her comeback step-by-step even if there’s plenty of reason to look down the road. For now, the 40-year-old American ski racer was concentrating on testing out the course as a forerunner. Soon, it will be her first World Cup race. Possibly later, the 2026 Winter Games at one of her favorite venues in Cortina d’Ampezzo, Italy. Vonn was one of three forerunners to test out the Birds of Prey course before the racers in the field went through a training run. Federica Brignone of Italy had the fastest time on a Birds of Prey course that’s new to quite a few racers.Brazil's top court takes on regulation of social media